The right ventricle in pulmonary hypertension

Pulmonary arterial hypertension (PAH) is a term used to classify a variety of conditions that share in common an injury to the pulmonary vasculature that produces elevations in pulmonary arterial pressure. However, it is the integrity of right ventricular function, rather than the degree of vascular injury, that is the major determinant of symptoms and survival in PAH. The article will review the normal structure and function of the right ventricle and summarize the impact of PAH and its treatments on right ventricular function.

[1]  C. Oakley,et al.  Factors that influence the outcome of primary pulmonary hypertension. , 1986, British heart journal.

[2]  G. Montalescot,et al.  Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. , 1998, The American journal of cardiology.

[3]  B. Groves,et al.  Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics , 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[4]  S. Mohr-Kahaly,et al.  Quantitative assessment of right ventricular volumes in severe chronic thromboembolic pulmonary hypertension using transthoracic three-dimensional echocardiography: changes due to pulmonary thromboendarterectomy. , 2002, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[5]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[6]  R. Saouaf,et al.  Validation of SPECT equilibrium radionuclide angiographic right ventricular parameters by cardiac magnetic resonance imaging , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[7]  T. Sundt,et al.  Lung transplantation for pulmonary vascular disease. , 2002, The Annals of thoracic surgery.

[8]  L. Rubin.  Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[9]  E. Trulock,et al.  Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  G. Mielke,et al.  Cardiac Output and Central Distribution of Blood Flow in the Human Fetus , 2001, Circulation.

[11]  J. Seward,et al.  Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. , 1985, Journal of the American College of Cardiology.

[12]  L. Girling,et al.  Treatment of shock in a canine model of pulmonary embolism. , 1984, The American review of respiratory disease.

[13]  J. Foster,et al.  Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure , 2002, European Respiratory Journal.

[14]  A. Waggoner,et al.  Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. , 2002, The American journal of cardiology.

[15]  J. Bronzwaer,et al.  Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. , 2004, Chest.

[16]  G. Castro.  [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study]. , 2001, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[17]  H. Knoblauch,et al.  Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A twin study. , 1997, Hypertension.

[18]  E. Trulock,et al.  Right and left ventricular dysfunction in patients with severe pulmonary disease. , 1998, Chest.

[19]  P. Lange,et al.  Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects , 1999, Heart.

[20]  M. B. Perryman,et al.  Importance of angiotensin-converting enzyme in pulmonary hypertension. , 1995, Cardiology.

[21]  A. Torbicki,et al.  Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension , 2003, Circulation.

[22]  S. Mohr-Kahaly,et al.  Pathophysiology of impaired right and left ventricular function in chronic embolic pulmonary hypertension: changes after pulmonary thromboendarterectomy. , 2000, Chest.

[23]  R. Matthay,et al.  The right ventricle in pulmonary disease. , 1992, Cardiology clinics.

[24]  E. Robin,et al.  PRIMARY PULMONARY HYPERTENSION , 2022 .

[25]  M. Sklansky,et al.  Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. , 1999, The American journal of cardiology.

[26]  N. Morrell,et al.  Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. , 2002, American journal of respiratory and critical care medicine.

[27]  J B Seward,et al.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.

[28]  F. Lallemand,et al.  Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.

[29]  R. Quaife,et al.  The pressure-overloaded right ventricle in pulmonary hypertension. , 1998, Chest.

[30]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[31]  G. Koch,et al.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[32]  A. Ambergen,et al.  The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[33]  F. Wackers,et al.  Assessment of right ventricular morphology and function. , 2003, Seminars in respiratory and critical care medicine.

[34]  B. Brundage,et al.  Pressure and volume loading of the right ventricle have opposite effects on left ventricular ejection fraction. , 1995, Circulation.

[35]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[36]  R. Virmani,et al.  Anatomy and pathology of the right ventricle (including acquired tricuspid and pulmonic valve disease). , 1992, Cardiology clinics.

[37]  K. Hirata,et al.  Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[38]  A. Van Tosh,et al.  Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. , 1985, Journal of the American College of Cardiology.

[39]  A. Wells,et al.  Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. , 1997, British journal of rheumatology.

[40]  H. Ito,et al.  Endothelins and cardiac hypertrophy. , 1997, Life sciences.

[41]  V. Aiello,et al.  Reversible pulmonary trunk banding. II. An experimental model for rapid pulmonary ventricular hypertrophy. , 2002, The Journal of thoracic and cardiovascular surgery.

[42]  J. Sandoval,et al.  Survival in primary pulmonary hypertension. Validation of a prognostic equation. , 1994, Circulation.

[43]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[44]  R. Favaloro,et al.  Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[45]  W. Kuebler,et al.  The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo , 2003, Intensive Care Medicine.

[46]  G. Koch,et al.  Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension , 1997 .

[47]  Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[48]  M. Hoeper,et al.  Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension , 2003, Heart.